Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06540066 · ClinicalTrials.gov registry record · Phase 1
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by BeiGene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT06540066 is a Phase 1 study that was terminated before completion, run by BeiGene. The registered enrollment target is 35 participants.
The verdict
NCT06540066, a Phase 1 study, was terminated before completion, sponsored by BeiGene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of BGB-B3227, a humanized immunoglobulin G1 (IgG1) antibody. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-B3227 as a monotherapy or in combination with tislelizumab with or without chemotherapy in participants with selected advanced or metastatic solid tumors. The study will also identify recommended dose(s) for expansion (RDFE\[s\]) of BGB-B3227 administered alone and in combination with tislelizumab.
Interventions
- DRUG Tislelizumab
- DRUG Chemotherapy
- DRUG BGB-B3227
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2024-09-11 |
| Est. Completion | 2026-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06540066
The ClinicalTrials.gov registry entry for NCT06540066 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tislelizumab is the first listed.
NCT06540066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06540066 about?
NCT06540066 is a clinical study titled "A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors". This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of BGB-B3227, a humanized immunoglobulin G1 (IgG1) antibody. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of B...
What is the current status of trial NCT06540066?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2024-09-11. Estimated completion is 2026-01-09.
What interventions are being tested in trial NCT06540066?
The interventions under investigation include: Tislelizumab (DRUG), Chemotherapy (DRUG), BGB-B3227 (DRUG).
Who is sponsoring clinical trial NCT06540066?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.